Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
Showing public results only.
Aditxt's filings show a precommercial health-innovation platform with immune, diagnostic, infectious-disease, women's-health, and proteomics ambitions, but the source-backed decision point is Nasdaq survival, cash, dilution, and whether any program can outrun
OpenRealty Income reported FY2025 revenue of $5.7 billion and Q1 2026 revenue of $1.5 billion. The thesis depends on lease durability, acquisition spreads, balance-sheet access, tenant concentration and cash conversion.
Open20/20 Biolabs has a real OneTest cancer-screening revenue base and a fresh Nasdaq listing, but FY2025 losses, negative cash flow, Streeterville financing and resale overhang keep AIDX in a high-risk coverage bucket.
OpeneXp World Holdings is now trading as AGNT after adding NextHome's franchise model to its cloud brokerage platform, but the equity case still has to prove agent retention, gross-profit conversion and legal resilience.
OpenA $4.5 million revenue base, a $47.4 million net loss, $25.2 million of cash, 132 Texas homes, and an $83.0 million related-party New Energy transaction make AEI a filing-reader's special situation rather than a simple real estate stock.
OpenAdvanced Biomed has historical cancer-diagnostics technology, but the latest filings show no product revenue, a reverse split, a short-term loan, a subsidiary divestiture, and an April 2026 pivot into AI.
OpenAdaptive's clonoSEQ MRD business is finally showing scale, but the proof gate is whether test volume, reimbursement, pharma milestones, and operating leverage can absorb cash burn and the OrbiMed revenue-interest obligation.
OpenAres Commercial Real Estate has renewed loan originations and expanded funding capacity, but Q1 2026 still showed a GAAP loss, a large CECL reserve, non-accrual CRE loans, and a dividend that needs stronger recurring earnings support.
OpenACRES Commercial Realty has a $2.2 billion CRE loan book, $29.98 of book value per share, and 96.2% of loans current on contractual payments, but the next real decision is whether a roughly 7.5 million-share internalization makes the common stock better or jus
OpenAclarion has a distinctive MRS-based spine diagnostic workflow, a stronger post-financing cash balance, and visible CLARITY and payer proof gates, but FY2025 revenue was only $75,730 and the company still has to convert Nociscan from clinical promise into reim
OpenAbbott's Medical Devices engine, led by diabetes care, is doing the heavy lifting while Nutrition weakens and the Exact Sciences acquisition adds cancer-diagnostics upside, debt, and integration risk.
OpenAgilent's CrossLab mix and cash generation point to a durable lab-workflow franchise, but the open question is whether service and consumables strength can outrun instrument-cycle volatility.
Open